Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeannette L Bennicelli

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Elife|August 31, 2013
Stem cells set their sights on retinitis pigmentosaJeannette L Bennicelli, Jean Bennett
Current Opinion in Oncology|July 20, 2002
Chromosomal translocations and sarcomasJeannette L Bennicelli, Frederic G Barr
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 9, 2004
Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expressionOana Tomescu, Shujuan J Xia, Donna Strezlecki, et al.
Science Translational Medicine|April 9, 2010
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindnessDefne Amado, Federico Mingozzi, Daniel Hui, et al.
Plos One|May 14, 2013
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized modelsVidyullatha Vasireddy, Jason A Mills, Rajashekhar Gaddameedi, et al.
Plos One|June 20, 2015
Correction: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized ModelsVidyullatha Vasireddy, Jason A Mills, Rajashekhar Gaddameedi, et al.
Science Translational Medicine|February 11, 2012
AAV2 gene therapy readministration in three adults with congenital blindnessJean Bennett, Manzar Ashtari, Jennifer Wellman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2009
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administrationFrancesca Simonelli, Albert M Maguire, Francesco Testa, et al.
Lancet (London, England)|July 5, 2016
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trialJean Bennett, Jennifer Wellman, Kathleen A Marshall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2018
Amelioration of Neurosensory Structure and Function in Animal and Cellular Models of a Congenital BlindnessJi Yun Song, Puya Aravand, Sergei Nikonov, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Elife|August 31, 2013
Stem cells set their sights on retinitis pigmentosaJeannette L Bennicelli, Jean Bennett
Current Opinion in Oncology|July 20, 2002
Chromosomal translocations and sarcomasJeannette L Bennicelli, Frederic G Barr
Laboratory Investigation; a Journal of Technical Methods and Pathology|June 9, 2004
Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expressionOana Tomescu, Shujuan J Xia, Donna Strezlecki, et al.
Science Translational Medicine|April 9, 2010
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindnessDefne Amado, Federico Mingozzi, Daniel Hui, et al.
Plos One|May 14, 2013
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized modelsVidyullatha Vasireddy, Jason A Mills, Rajashekhar Gaddameedi, et al.
Plos One|June 20, 2015
Correction: AAV-Mediated Gene Therapy for Choroideremia: Preclinical Studies in Personalized ModelsVidyullatha Vasireddy, Jason A Mills, Rajashekhar Gaddameedi, et al.
Science Translational Medicine|February 11, 2012
AAV2 gene therapy readministration in three adults with congenital blindnessJean Bennett, Manzar Ashtari, Jennifer Wellman, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 3, 2009
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administrationFrancesca Simonelli, Albert M Maguire, Francesco Testa, et al.
Lancet (London, England)|July 5, 2016
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trialJean Bennett, Jennifer Wellman, Kathleen A Marshall, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2018
Amelioration of Neurosensory Structure and Function in Animal and Cellular Models of a Congenital BlindnessJi Yun Song, Puya Aravand, Sergei Nikonov, et al.
Pageof 2